UNLABELLED: Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis and hepatocellular carcinoma (HCC). Both advanced solid tumors and HCV have previously been associated with memory B-cell dysfunction. In this study, we sought to dissect the effect of viral infection, cirrhosis, and liver cancer on memory B-cell frequency and function in the spectrum of HCV disease. Peripheral blood from healthy donors, HCV-infected patients with F1-F2 liver fibrosis, HCV-infected patients with cirrhosis, patients with HCV-related HCC, and non-HCV-infected cirrhotics were assessed for B-cell phenotype by flow cytometry. Isolated B cells were stimulated with anti-cluster of differentiation (CD)40 antibodies and Toll-like receptor (TLR)9 agonist for assessment of costimulation marker expression, cytokine production, immunoglobulin (Ig) production, and CD4(+) T-cell allostimulatory capacity. CD27(+) memory B cells and, more specifically, CD27(+) IgM(+) B cells were markedly less frequent in cirrhotic patients independent of HCV infection. Circulating B cells in cirrhotics were hyporesponsive to CD40/TLR9 activation, as characterized by CD70 up-regulation, tumor necrosis factor beta secretion, IgG production, and T-cell allostimulation. Last, blockade of TLR4 and TLR9 signaling abrogated the activation of healthy donor B cells by cirrhotic plasma, suggesting a role for bacterial translocation in driving B-cell changes in cirrhosis. CONCLUSION: Profound abnormalities in B-cell phenotype and function occur in cirrhosis independent of HCV infection. These B-cell defects may explain, in part, the vaccine hyporesponsiveness and susceptibility to bacterial infection in this population.
UNLABELLED: Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis and hepatocellular carcinoma (HCC). Both advanced solid tumors and HCV have previously been associated with memory B-cell dysfunction. In this study, we sought to dissect the effect of viral infection, cirrhosis, and liver cancer on memory B-cell frequency and function in the spectrum of HCV disease. Peripheral blood from healthy donors, HCV-infectedpatients with F1-F2 liver fibrosis, HCV-infectedpatients with cirrhosis, patients with HCV-related HCC, and non-HCV-infected cirrhotics were assessed for B-cell phenotype by flow cytometry. Isolated B cells were stimulated with anti-cluster of differentiation (CD)40 antibodies and Toll-like receptor (TLR)9 agonist for assessment of costimulation marker expression, cytokine production, immunoglobulin (Ig) production, and CD4(+) T-cell allostimulatory capacity. CD27(+) memory B cells and, more specifically, CD27(+) IgM(+) B cells were markedly less frequent in cirrhotic patients independent of HCV infection. Circulating B cells in cirrhotics were hyporesponsive to CD40/TLR9 activation, as characterized by CD70 up-regulation, tumor necrosis factor beta secretion, IgG production, and T-cell allostimulation. Last, blockade of TLR4 and TLR9 signaling abrogated the activation of healthy donor B cells by cirrhotic plasma, suggesting a role for bacterial translocation in driving B-cell changes in cirrhosis. CONCLUSION: Profound abnormalities in B-cell phenotype and function occur in cirrhosis independent of HCV infection. These B-cell defects may explain, in part, the vaccine hyporesponsiveness and susceptibility to bacterial infection in this population.
Authors: Jianhua Ni; Edgardo Hembrador; Adrian M Di Bisceglie; Ira M Jacobson; Andrew H Talal; David Butera; Charles M Rice; Thomas J Chambers; Lynn B Dustin Journal: J Immunol Date: 2003-03-15 Impact factor: 5.422
Authors: C Guarner; G Soriano; A Tomas; O Bulbena; M T Novella; J Balanzo; F Vilardell; M Mourelle; S Moncada Journal: Hepatology Date: 1993-11 Impact factor: 17.425
Authors: Sonia Pascual; José Such; Angel Esteban; Pedro Zapater; Juan A Casellas; José R Aparicio; Eva Girona; Ana Gutiérrez; Fernando Carnices; Jose M Palazón; Javier Sola-Vera; Miguel Pérez-Mateo Journal: Hepatogastroenterology Date: 2003 Sep-Oct
Authors: José Such; Rubén Francés; Carlos Muñoz; Pedro Zapater; Juan A Casellas; Ana Cifuentes; Francisco Rodríguez-Valera; Sonia Pascual; Javier Sola-Vera; Fernando Carnicer; Francisco Uceda; José M Palazón; Miguel Pérez-Mateo Journal: Hepatology Date: 2002-07 Impact factor: 17.425
Authors: E A Frey; D S Miller; T G Jahr; A Sundan; V Bazil; T Espevik; B B Finlay; S D Wright Journal: J Exp Med Date: 1992-12-01 Impact factor: 14.307
Authors: Georgios I Tsiaoussis; Stelios F Assimakopoulos; Athanassios C Tsamandas; Christos K Triantos; Konstantinos C Thomopoulos Journal: World J Hepatol Date: 2015-08-18
Authors: Mustimbo E P Roberts; Denise Kaminski; Scott A Jenks; Craig Maguire; Kathryn Ching; Peter D Burbelo; Michael J Iadarola; Alexander Rosenberg; Andreea Coca; Jennifer Anolik; Iñaki Sanz Journal: Arthritis Rheumatol Date: 2014-09 Impact factor: 10.995
Authors: Manoj Thapa; Dana Tedesco; Sanjeev Gumber; Elizabeth J Elrod; Jin-Hwan Han; William H Kitchens; Joseph F Magliocca; Andrew B Adams; Arash Grakoui Journal: J Immunol Date: 2020-04-24 Impact factor: 5.422